Franklin Covey offers visible and predictable growth in the $55B management training market, so don't sell the company's stock despite its surging price, says Michael Balkin, portfolio manager for the William Blair Small Cap Growth Fund. Balkin says Ligand Pharmaceuticals shares are also a smart buy because the biotech has 7 royalty producing drugs and another 90 in the pipeline. Finally, Balkin is bullish on CoStar Group's stock, saying the company is the Bloomberg of the real estate space. While the stock trades at a high multiple to sales and earnings, Balkin says it has highly visible recurring revenue and a long runway for growth.